Edition:
United States

Halozyme Therapeutics Inc (HALO.O)

HALO.O on Nasdaq

9.29USD
25 Jul 2016
Change (% chg)

$0.05 (+0.54%)
Prev Close
$9.24
Open
$9.30
Day's High
$9.38
Day's Low
$9.10
Volume
708,456
Avg. Vol
1,550,583
52-wk High
$25.00
52-wk Low
$6.96

Select another date:

BRIEF-Halozyme to resume enrollment in Phase 1B trial evaluating PEGPH20

* Resumed enrollment, dosing patients in phase 1B trial evaluating investigational new drug, PEGPH20, in combination with KEYTRUDA

BRIEF-Halozyme announces agreement to refinance debt

* Entered into agreement with Oxford Finance Llc and Silicon Valley Bank to refinance its existing senior secured loan facility

BRIEF-Halozyme Q1 loss per share $0.16

* Halozyme therapeutics inc sees 2016 net revenues to be in range of $130 million to $145 million

BRIEF-Halozyme Therapeutics expands oncology pipeline with two compounds designed for activity in tumor microenvironment

* Says halozyme expands oncology pipeline with two compounds designed for activity in tumor microenvironment Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Halozyme doses first patient in phase 3 clinical trial of PEGPH20 in combination with ABRAXANE and Gemcitabine

* Halozyme doses first patient in phase 3 clinical trial of pegph20 in combination with abraxane and gemcitabine

Select another date: